Helix BioMedix, Grant Industries say new acne solution shows promising results

By Elaine Rigoli

Tampa, Fla., March 20 - Helix BioMedix, Inc. and Grant Industries announced the successful results of a human panel test for Grant's new proprietary acne blend for use in over-the-counter acne products.

The acne solution, Granactive, combines Helix BioMedix's proprietary Oligopeptide-10 with salicylic acid and Grant's Invisiskin, an ingredient used to enhance delivery of bioactive compounds.

The panel test compared a formulation containing Granactive with Oligopeptide-10 to a market-leading benzoyl peroxide product in treating grade 3 (moderate) or greater acne conditions, according to a news release.

Results of the panel test showed that treatment with Granactive was clearly superior in reducing the number of comedone (non-inflammatory) lesions at each evaluation, the release said.

In addition, Granactive treatment resulted in significantly fewer comedones after only seven days of use indicating efficacy that was not only superior but also more rapid, the release said.

Counts of other lesion types associated with the condition of acne (papules, pustules and cysts) corroborated the comedone data. Irritation decreased throughout the six-week evaluation with both treatments, and these scores were significantly reduced at days 28 and 42 with the Granactive formulation.

"The results of the human panel test of our new anti-acne blend which contains Helix BioMedix's Oligopeptide-10 exceeded our expectations. The U.S. market for anti-acne products sold over the counter is estimated at $488 million and we believe there is a significant opportunity for product enhancements," said Paul Granatell, executive director of Grant Industries, in a statement.

Grant Industries, located in Elmwood Park, N.J., is involved in the research, development, manufacturing and marketing of cosmetic, textile and performance specialty chemicals.

Helix BioMedix is a biopharmaceutical company located in Bothell, Wash.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.